Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCATCo Regulatory News (CAT)

  • This share is currently suspended. It was suspended at a price of 37.50
  • There is currently no data for CAT

Portfolio Update

2 Feb 2018 07:00

RNS Number : 7140D
CATCo Reinsurance Opps Fund Ltd
02 February 2018
 

 

 

 

CATCo Reinsurance Opportunities Fund Ltd. ("the Company")

Portfolio Update

 

To: SFM, London Stock Exchange and Bermuda Stock Exchange

Date: 2 February, 2018

 

2018 Portfolio Highlights

· As a result of the 2017 catastrophic events and increases in rates, the 2018 portfolio indicative maximum net return is approximately 23 percent on invested capital (c. 43 percent greater than the 2017 portfolio maximum net returns of 16 percent). These figures are all net of hedging costs.

· The maximum capital exposed to a worst-case single event is limited to 8 percent for the 2018 portfolio, compared to 10 percent for the 2017 portfolio.

· Continued increased demand for Markel CATCo Re Ltd. (the "Reinsurer") products has led to 100 percent of available capital being deployed at 1 January 2018.

 

2017 Portfolio Summary

· 2017 net asset value ("NAV") return for the Ordinary shares was -27.6 percent.

· Loss reserves were implemented in an amount as a percent of 1 January 2017 NAV as follows:

o Hurricanes Harvey, Irma and Maria: c. 28.6 percent (net of recoveries on hedges);

o California Wildfires: c. 17 percent;

o Mexico Earthquakes, Cyclone Debbie, US Convective Storms: c. 2 percent.

· The total Side Pocket Investments ("SPI's") held at 31 December 2017 by calendar year of underwriting are as follows as a percentage of the Company's 1 January 2017 NAV:

o 2015: c. 1.2 percent (c. 3.2 percent of Ordinary shares at 31 December 2016);

o 2016: c. 6.1 percent (c. 7.1 percent of Ordinary and C shares at 31 December 2016);

o 2017: c. 41.5 percent.

· The 2017 annual dividend was announced on 31 January 2018. Annual dividends of $0.05476 in respect of each of the Ordinary shares will go ex-dividend on 8 February 2018. It is expected that this dividend will be paid to Ordinary shareholders on 26 February 2018.

· After reflecting 2017 SPIs and loss reserves, the Ordinary shares, post dividend, will have c. 35 percent of NAV available for reinvestment in the 2018 portfolio.

· Since inception (incl. the aforementioned dividend), the Company has returned capital of $234m to Ordinary and C share investors by way of dividends and return of value distributions. The original Ordinary Shareholders from December 2010 have received approximately 75% of their original investment through such distributions.

 

 

For further information:

Judith Wynne

General Counsel

Markel CATCo Investment Management Ltd.

Telephone: +1 441 493 9005

Email: judith.wynne@markelcatco.com

 

Mark Way

Chief Operating Officer

Markel CATCo Investment Management Ltd.

Telephone: +1 441 493 9001

Email: mark.way@markelcatco.com

 

David Benda / Hugh Jonathan

Numis Securities Limited

Telephone: +44 (0) 20 7260 1000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PFUDDGDDRBGBGIB
Date   Source Headline
29th Mar 201111:40 amRNSIssue of Equity
29th Mar 201111:36 amRNSDirector/PDMR Shareholding
7th Mar 20111:49 pmRNSNet Asset Value(s)
7th Feb 20118:30 amRNSPortfolio Update
7th Feb 20118:11 amRNSNet Asset Value(s)
14th Jan 20117:00 amRNSPortfolio Update
7th Jan 20113:33 pmRNSHolding(s) in Company
23rd Dec 201011:00 amRNSHolding(s) in Company
20th Dec 20107:00 amRNSResult of Placing and Admission to SFM
13th Jul 20064:12 pmRNSHolding(s) in Company
10th Jul 20063:20 pmRNSHolding(s) in Company
7th Jul 20062:51 pmRNSOffer for Cambridge Antibody
3rd Jul 20064:56 pmRNSDirectorate Change
30th Jun 20064:12 pmRNSHolding(s) in Company
30th Jun 20064:06 pmRNSDelisting
30th Jun 200610:27 amRNSAdditional Listing
30th Jun 20067:02 amRNSOffer for Cambridge Antibody
27th Jun 20062:26 pmRNSHolding(s) in Company
27th Jun 200612:34 pmRNSHolding(s) in Company
23rd Jun 20062:25 pmRNSAppointment of Directors
22nd Jun 20063:07 pmRNSRule 8.3- CAT
22nd Jun 200611:31 amRNSCAT Limited appoints new CE
22nd Jun 200611:11 amRNSEPT Disclosure
22nd Jun 200611:09 amRNSEPT Disclosure
22nd Jun 20067:02 amRNSOffer for Cambridge Antibody
21st Jun 20065:11 pmRNSRule 8.1- C.A.T.
21st Jun 200611:30 amRNSEPT Disclosure
21st Jun 200610:20 amRNSEPT Disclosure
20th Jun 200610:36 amRNSEPT Disclosure
20th Jun 200610:36 amRNSEPT Disclosure
19th Jun 20063:25 pmRNSRule 8.3 - Cambridge Antibody
19th Jun 20061:07 pmRNSRule 8.3- (CAT)
19th Jun 200611:30 amRNSEPT Disclosure
19th Jun 200611:23 amRNSEPT Disclosure
19th Jun 200610:33 amRNSEPT Disclosure
16th Jun 200611:45 amRNSEPT Disclosure
16th Jun 200611:24 amRNSEPT Disclosure
16th Jun 200611:08 amRNSEPT Disclosure
15th Jun 20065:01 pmRNSEPT Disclosure
15th Jun 20062:48 pmRNSRule 8.3- (CAT)
15th Jun 20062:17 pmRNSRule 2.10 Announcement
15th Jun 200612:45 pmRNSEPT Disclosure
15th Jun 200611:36 amRNSEPT Disclosure
14th Jun 20063:38 pmRNSRule 8.3- Cambridge Antibody
14th Jun 20063:05 pmRNSRule 8.3- Cambridge Antibody
14th Jun 20061:43 pmRNSRule 8.3- (CAT)
14th Jun 200611:36 amRNSEPT Disclosure
14th Jun 200611:15 amRNSEPT Disclosure
14th Jun 200610:59 amRNSEPT Disclosure
14th Jun 200610:23 amRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.